Rhumbline Advisers Raises Holdings in Edwards Lifesciences Co. (NYSE:EW)

Rhumbline Advisers lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 4.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,130,154 shares of the medical research company's stock after acquiring an additional 44,249 shares during the quarter. Rhumbline Advisers owned approximately 0.19% of Edwards Lifesciences worth $81,913,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $27,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $30,000. Finally, Park Square Financial Group LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $44,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research note on Monday. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Citigroup reaffirmed a "buy" rating and set a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Finally, Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Hold" and an average price target of $80.20.

Edwards Lifesciences Stock Down 0.2%

Shares of NYSE EW traded down $0.15 during trading on Thursday, reaching $77.70. The company had a trading volume of 2,161,186 shares, compared to its average volume of 5,189,652. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market cap of $45.58 billion, a PE ratio of 11.15, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The business's 50-day moving average is $73.76 and its 200 day moving average is $72.64.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. During the same period last year, the firm posted $0.66 earnings per share. Edwards Lifesciences's revenue was up 6.2% compared to the same quarter last year. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,153,526.69. The trade was a 27.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president now owns 50,356 shares of the company's stock, valued at $3,897,554.40. This represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,012 shares of company stock worth $4,224,717. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.